Use of Atezolizumab and Bevacizumab to Treat Advanced HCC
In recent years, significant progress has been made in treating advanced unresectable...
Read More
Meeting Coverage
Utilizing Genomic Features and Protein Markers for MRD Detection in HCC Patients
Many researchers determined that the clinical significance of circulating tumor DNA (ctDNA) in...
Read More
Impacting OS in Patients with Unresectable HCC with 1L TIS
Tislelizumab (TIS) is a specific monoclonal antibody targeting programmed cell death protein 1...
Read More
Adjuvant Atezolizumab Impact on Recurrence Prevention and Cost Reduction in Early PD-L1 High NSCLC
Recurrent cases of non-small cell lung cancer (NSCLC) following surgery are common and carry...
Read More
Race and Curative-Intent Treatment Linked To Mortality Outcomes in Early-Stage NSCLC
In recent decades, persistent disparities in the survival of individuals with early-stage...
Read More
New Blood-Based RNA Platform for Early Lung Cancer Diagnosis
Blood-based methods utilizing circulating tumor DNA (ctDNA) and cell-free DNA (cfDNA) are...
Read More
CtDNA as Outcome Predictor in NSCLC Undergoing Targeted Therapies: A Meta-Analysis
For treating non-small cell lung cancer (NSCLC), liquid biopsy (LB) was analyzed using...
Read More
Adjuvant Chemotherapy in High-Risk, Early-Stage NSCLC with Clinical and Pathologic Features Reevaluated
Surgical resection is the preferred treatment for early-stage non-small cell lung cancer (NSCLC),...
Read More
FOF and Concern of Falling in Patients with Relapsing-Remitting or Progressive MS
Frequent falls and the fear of falling (FOF) are significant challenges experienced by individuals...
Read More
Mindfulness-Based Stress Reduction in MS: Correlates of Patient-Reported Outcomes and MRI Findings
Researchers conducted a study to examine the effects of mindfulness-based stress reduction (MBSR)...
Read More
Low-Fat Diet Trial: Assessing Fatigue in Multiple Sclerosis
Fatigue is a common and debilitating symptom among individuals with multiple sclerosis (MS)....
Read More
Pharmacological Comparison of Tolebrutinib with Other BTK Inhibitor Candidates for MS Treatment
Tolebrutinib, a covalent inhibitor of Bruton tyrosine kinase (BTK), has been specifically...
Read More
MRI Results of Tolebrutinib Long-Term Safety Extension Study in Relapsing MS
Tolebrutinib, a potent inhibitor of Bruton tyrosine kinase that can cross the blood-brain barrier,...
Read More
Why Attend CMSC
From CMSC’s Annual Meeting brochure: The Consortium of Multiple Sclerosis Centers (CMSC) has...
Read More
Quick Glance At CMSC Schedule
Take a look at CMSC’s Wednesday schedule: 8:00 am – 9:30 am ISS1 Independently...
Read More
MS Therapies Not Associated With Pregnancy Complications
A registry data analysis concluded that most disease-modifying therapies for MS are not associated...
Read More
5th Annual More About MS Patient Program
Managing Invisible Symptoms | June 2, 2023 “More About MS: Taking Charge of Your MS Care” will be...
Read More
Ancillary Educational Events
Ancillary events are functions held adjacent to the ASCO Annual Meeting, including, but not...
Read More
Communities of Practice
Connect with colleagues that share your passion and goals through one of ASCO’s new Communities of...
Read More
ASCO Voices
ASCO Voices continues to be one of the most compelling sessions offered at the ASCO Annual...
Read More